A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO).

Inclusion Criteria: 1. Adult aged 25-80 2. Patient understands and has signed the study informed consent form. 3. Patient has symptomatic peripheral artery disease (PAD) requiring endovascular revascularization of a CTO, evidenced by angiography, computed tomography or magnetic resonance angiography. 4. Patient has an occluded femoropopliteal or infra popliteal artery 5. Target femoropopliteal or infra-popliteal vessel is ≥ 2.5 mm and ≤5 mm in diameter. 6. Patient has Rutherford-Becker Classification of 2-5. Exclusion Criteria: 1. Patient unable to give informed consent. 2. Current participation in another study with any investigational drug or device. 3. Patient has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated. 4. Patient has a known sensitivity or allergy to anti-platelet medications. 5. Patient is pregnant or lactating. 6. Patient has a co-existing disease or medical condition contraindicating percutaneous intervention. 7. Target lesion is in a bypass graft. 8. Target lesion is in a stent (i.e., in-stent restenosis). 9. Patient has had a procedure on the target limb within 7 days. 10. Patient had undergone attempted treatment of the CTO within the prior 3 months (to prevent a guidewire from entering dissection planes created by prior recanalization attempts. 11. Vasculitis and Buerger disease (thrombendarteritis obliterans) 12. Evidence of embolism 13. Peripheral vessel aneurysm